Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Certara's latest quarterly earnings reveal a mixed set of financial and operational conditions that provide both promising prospects and certain challenges.</li><li>The company reported third-quarter revenue of $94.8 million, an 11% year-over-year increase.</li><li>This was bolstered by a 13% rise in total bookings, signaling a steady demand for Certara's biosimulation services in the global drug development industry.</li></ul>

Certara's latest quarterly earnings reveal a mixed set of financial and operational conditions that provide both promising prospects and certain challenges.The company reported third-quarter revenue of $94.8 million, an 11% year-over-year increase.This was bolstered by a 13% rise in total bookings, signaling a steady demand for Certara's biosimulation services in the global drug development industry.

Certara Inc.: Will Its Integration & Expansion via Strategic Acquisitions Be A Breakthrough Move? - Major Drivers

<ul><li>Certara reported its first-quarter financial results for 2024, detailing a period of structured progress and proactive initiatives aimed at solidifying and expanding its position in the pharmaceutical software and technology-driven services space.</li><li>Revenues for the quarter totaled $96.7 million, marking a 7% growth on a reported basis and 6% on a constant currency basis, compared to the prior year.</li><li>This increment was supported by robust demand for Certara’s biosimulation software and services, complemented by a burgeoning interest in AI-enhanced products after its recent acquisition of Vyasa.</li></ul>

Certara reported its first-quarter financial results for 2024, detailing a period of structured progress and proactive initiatives aimed at solidifying and expanding its position in the pharmaceutical software and technology-driven services space.Revenues for the quarter totaled $96.7 million, marking a 7% growth on a reported basis and 6% on a constant currency basis, compared to the prior year.This increment was supported by robust demand for Certara’s biosimulation software and services, complemented by a burgeoning interest in AI-enhanced products after its recent acquisition of Vyasa.

Certara Inc.: Introduction of Unified Certara Cloud Platform & Major Drivers

<ul><li>This is our first report on Certara, a renowned biosimulation player.</li><li>The company recently released its Fourth Quarter 2023 Earnings.</li><li>In terms of performance, the company reported revenue growth of 6% for the year, in line with their guidance from August 2023.</li></ul>

This is our first report on Certara, a renowned biosimulation player.The company recently released its Fourth Quarter 2023 Earnings.In terms of performance, the company reported revenue growth of 6% for the year, in line with their guidance from August 2023.

Certara Inc.: Initiation Of Coverage -  A Diverse Product Portfolio & Interesting AI Initiatives! - Major Drivers

United States

Certara, Inc. operates as a bio-technology company. The Company focuses on accelerating medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. Certara serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Certara (CERT US)

Certara Inc.: Will Its Integration & Expansion via Strategic Acquisitions Be A Breakthrough Move? - Major Drivers

Certara's latest quarterly earnings reveal a mixed set of financial and operational conditions that provide both promising prospects and certain...

Baptista Research

Certara Inc.: Introduction of Unified Certara Cloud Platform & Major Drivers

Certara reported its first-quarter financial results for 2024, detailing a period of structured progress and proactive initiatives aimed at...

Baptista Research

Certara Inc.: Initiation Of Coverage - A Diverse Product Portfolio & Interesting AI Initiatives! - Major Drivers

This is our first report on Certara, a renowned biosimulation player. The company recently released its Fourth Quarter 2023 Earnings. In terms of...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)